Baillie Gifford & CO Cure Vac N.V. Transaction History

Baillie Gifford & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$13.18 - $19.41 $47.8 Million - $70.3 Million	-3,624,098 Reduced 92.66%	287,249 $3.91 Million
Q1 2022 May 05, 2022	SELL	$14.73 - $35.25 $176,656 - $422,753	-11,993 Reduced 0.31%	3,911,347 $76.7 Million
Q4 2021 Jan 20, 2022	SELL	$33.72 - $48.22 $586,424 - $838,594	-17,391 Reduced 0.44%	3,923,340 $135 Million
Q3 2021 Oct 19, 2021	SELL	$49.26 - $74.5 $77.6 Million - $117 Million	-1,574,531 Reduced 28.55%	3,940,731 $215 Million
Q2 2021 Aug 02, 2021	SELL	$56.91 - $127.53 $17.9 Million - $40.2 Million	-314,839 Reduced 5.4%	5,515,262 $405 Million
Q1 2021 May 06, 2021	BUY	$79.79 - $126.29 $82.1 Million - $130 Million	1,028,445 Added 21.42%	5,830,101 $533 Million
Q4 2020 Feb 10, 2021	BUY	$46.76 - $136.27 $42.3 Million - $123 Million	905,181 Added 23.23%	4,801,656 $389 Million
Q3 2020 Nov 12, 2020	BUY	$43.8 - $77.2 $171 Million - $301 Million	3,896,475 New	3,896,475 $181 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.